Novo Nordisk (CPSE:NOVO B) Stock Looks Cheap Even With Rival Pressure

What happened: Novo Nordisk shares have come under pressure, with the stock down 59.6% over the past 3 years, as fresh Eli Lilly trial data showed retatrutide outperforming Ozempic and rival GLP-1 treatments advanced on regulation. Key numbers: Stock down 59.6% over 3 years. Why it matters: The article says the current multiple still prices Novo Nordisk at a discount to both its sector and peer set, while the bull and bear narratives disagree on whether the price reflects deep value or already full expectations. Market: +0.5% today ($1,288.30), +19.7% YTD, 0.8x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 29) revenue $21.7B vs $21.7B est; next print ~Jan 28

Novo Nordisk shares have come under pressure, with the stock down 59.6% over the past 3 years, as fresh Eli Lilly trial data showed retatrutide outperforming Ozempic and rival GLP-1 treatments advanced on regulation.

The article says the current multiple still prices Novo Nordisk at a discount to both its sector and peer set, while the bull and bear narratives disagree on whether the price reflects deep value or already full expectations. Market: +0.5% today ($1,288.30), +19.7% YTD, 0.8x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 29) revenue $21.7B vs $21.7B est; next print ~Jan 28